Search
GT 389-255
go.drugbank.com/drugs/DB05894ExperimentalPeptimmune’s lead product GT 389-255, is a novel lipase inhibitor and fat binding hydrogel polymer conjugate for the treatment of obesity which has completed single and multiple ascending dose (SAD and MAD) Phase I trials. It is expected...
HMR4011
go.drugbank.com/drugs/DB06225ExperimentalHMR4011 (IPL 576,092) is a novel steroidal anti-inflammatory compound with a mechanism of action distinct from that of glucocorticoid. IPL 576,092 has previously been investigated as a treatment for asthma.
MAHDL01
go.drugbank.com/drugs/DB06270ExperimentalMAHDL01 is a pharmaceutical combination of whole plants, which is used to increase the HDL/LDL ratio that improves overall cardiovascular health.
Carbomycin
go.drugbank.com/drugs/DB11383ExperimentalVet approvedThe structure of carbomycin was generated in 1957 by Robert Woodward and later modified in 1965.
Sparfosic acid
go.drugbank.com/drugs/DB03459ExperimentalThis compound belongs to the n-acyl-alpha amino acids. These are compounds containing an alpha amino acid which bears an acyl group at the terminal nitrogen atom.
Synonyms: N-(phosphonacetyl)-L-aspartic acid, N-phosphonacetyl-L-aspartic acidFroniglutide
go.drugbank.com/drugs/DB16178InvestigationalThree Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM). … Glymera is under investigation in clinical trial NCT01658501 (Phase 2b Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group Study to Assess the PD Response and Safety of
Risvutatug rezetecan
go.drugbank.com/drugs/DB23560InvestigationalIt is under investigation in clinical trial NCT06885034 (A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers